In 41 adults and adolescents with eosinophilic gastritis (40 analysed), 12 weeks of dupilumab reduced gastric eosinophil counts more than placebo (mean relative change −50% vs −4%; difference −47 points, p<0·0001). Adverse events were similar (81% vs 85%).
RCTn = 41
Gonsalves et al. Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial